openPR Logo
Press release

Latest Research Report on Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation

Latest Research Report on Chronic Obstructive Pulmonary

Researchmoz added Most up-to-date research on "Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports.

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity and the fifth-leading cause of death in the world. COPD is linked to cumulative exposure to risk factors, primarily tobacco smoke, but also environmental pollutants. The COPD marketed products landscape consists of pharmacological therapies aimed at managing the symptoms associated with COPD, although none of the available therapies have been shown to modify long-term disease progression.

The current COPD pipeline consists of 212 active products in development. Initial analysis revealed a small presence of first-in-class products, constituting 16.5% of the pipeline. In comparison to other indications, this is relatively low; however, there are some promising trends within COPD product development. The Preclinical Phase of development is the most active in terms of first-in-class products. This diminishes throughout clinical development, with only two such products being present in Phase III. However, if either of these products is approved, they would represent the first, first-in-class products to be approved for COPD since roflumilast, which was approved in 2011 by the FDA and in 2010 in the EU. Roflumilast was the first novel therapy for COPD in almost 20 years, which demonstrates the infrequency at which first-in-class products enter the COPD market. So to have two first-in-class products in Phase III and six in Phase II is a promising sign.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=536325

Scope

- The COPD market has benefited from notable additions in recent years.

- Which classes of drug dominate the market?

- What additional benefits have newly approved therapies brought to market?

- How do the leading marketed therapies compare clinically?

- The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD and novel, first-in-class therapies.

- Which molecular targets appear most frequently in the pipeline?

- To what degree is the pipeline penetrated by first-in-class innovation?

- Which target families consist of the most first-in-class products?

- First-in-class products differ substantially in their clinical potential, based on their alignment to disease causing pathways.

- How well are first-in-class targets aligned to known disease causing pathways?

- Which targets are specifically found in early-stage development?

- What is the industry-wide interest in these targets?

- Which are the most promising first-in-class targets in early-stage development?

- There have been 59 licensing deals and 41 co-development deals pertaining to COPD products since 2006.

- Which territories show the most deal activity?

- What were the trends in deal completion by product stage of development?

- How many deals involved first-in-class products?

- Which of the first-in-class products in development are not currently involved in a licensing or co-development deal, and therefore represent investment opportunities?

Reasons To Buy
- This report will allow you to:

- Understand the current clinical and commercial landscape. It includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis.

- Visualize the composition of the COPD market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.

- Analyze the COPD pipeline and stratify by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating COPD.

- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.

- Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of COPD therapies that are not yet involved in deals and may be potential investment opportunities.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=536325

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ http://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Follow us on LinkedIn @ http://bit.ly/1TBmnVG

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Latest Research Report on Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation here

News-ID: 489877 • Views:

More Releases from Chronic Obstructive Pulmonary Disease

Demands of Chronic Obstructive Pulmonary Disease Global Industry : Analysis, Growth, Market Status, 2017-2021
Demands of Chronic Obstructive Pulmonary Disease Global Industry : Analysis, Gro …
Researchmoz added Most up-to-date research on "Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports. Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity and the fifth-leading cause of death in the
Symptoms Of Chronic Obstructive Pulmonary Disease Including Shortness Of Breath, Wheezing, Chest Tightness, Cough - Global Drug Forecast and Market Analysis to 2025
Symptoms Of Chronic Obstructive Pulmonary Disease Including Shortness Of Breath, …
ResearchMoz presents this most up-to-date research on "Symptoms Of Chronic Obstructive Pulmonary Disease Including Shortness Of Breath, Wheezing, Chest Tightness, Cough - Global Drug Forecast and Market Analysis to 2025". Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by an abnormal inflammatory response and airflow obstruction that is not fully reversible. Chronic airflow limitation is caused by both small airway diseases, such as obstructive bronchiolitis, as well as

More Releases for COPD

Copd Drugs Market Size Analysis by Application, Type, and Region: Forecast to Co …
USA, New Jersey- According to Market Research Intellect, the global Copd Drugs market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period. Because respiratory problems are becoming more common worldwide, especially among smokers and older populations, the market for COPD medications is expanding steadily. The need
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market 2024-2030 Growth: …
Growth: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Insights : For stakeholders, an optimistic view is shown by the thorough study of the worldwide "Chronic Obstructive Pulmonary Disease (COPD) Treatment market". The research provides specifics on the market's historical and present conditions as well as projected trends and size. Decision-makers may navigate the competitive environment and investment possibilities in the Chronic Obstructive Pulmonary Disease (COPD) Treatment market with the use of
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market - Breathing Sol …
Newark, New Castle, USA - new report, titled Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Obstructive Pulmonary Disease
Asthma & COPD Drugs Market - Breathe Freely, Live Fully: Empowering Respiratory …
Newark, New Castle, USA - new report, titled Asthma & COPD Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Asthma & COPD Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Asthma & COPD Drugs market. The report offers
Copd CBD Gummies: Reviews (Shocking Facts) Copd CBD Oil "Ingredients" Pain Relie …
Copd CBD Gummies: With the increasing need for both individual and expert degrees, the stress and also stress are also enhancing. Individuals are using various methods to fight it. However, as a result of much less time for self, it is really hard. Here the natural herbs and supplements have actually discovered their way into our lives. The Copd CBD Oil are instances of super-effective natural supplements. The CBD existing
Power Harmonica to Cure Chronic Asthma & COPD
Power Harmonica is a free reed wind musical instrument. It is small rectangular shaped musical instrument. It has 48 number of holes which makes it special and different from other harmonica's. It's a pocket-friendly musical instrument. Power Harmonica is used as a natural treatment for many types of lung disorders and has no side effects. To play Power Harmonica there is no need of having a musical background it can be